Search

Displaying results 5071 - 5080 of 7452 in total
  1. Drug

    ORG-34517

    go.drugbank.com/drugs/DB05423
    Investigational

    ORG-34517 is currently under investigation by Organon for the treatment of depression.

  2. Drug

    Merimepodib

    go.drugbank.com/drugs/DB04862
    Investigational

    Merimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH. Merimepodib is orally bioavailable and inhibits the proliferation of primary human, mouse, rat, and dog lymphocytes at concentrations of approximately 100 nM.

  3. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for

  4. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  5. Drug

    NDX-3315

    go.drugbank.com/drugs/DB18671
    Investigational

    NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].

  6. Drug

    Palazestrant

    go.drugbank.com/drugs/DB18971
    Investigational

    Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).

  7. Drug

    Nelonicline

    go.drugbank.com/drugs/DB19040
    Investigational

    Nelonicline is under investigation in clinical trial NCT01678755 (A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia).

  8. Drug

    Atilotrelvir

    go.drugbank.com/drugs/DB19439
    Investigational

    Atilotrelvir is under investigation in clinical trial NCT05041907 (Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)).

  9. Drug

    OS2966

    go.drugbank.com/drugs/DB17207
    Investigational

    OS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]

  10. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    It is currently being investigated in clinical trials for the treatment of cancer.